FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:202-206 July 9, 2009 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Barry, M. J. Related Article by Andriole, G. L. Related Article by Schröder, F. H. PubMed Citation

To the Editor: The results of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (ClinicalTrials.gov number, NCT00002540 [ClinicalTrials.gov] ) by Andriole et al.¹ were released prematurely, at the same time that Schröder et al.² were reporting, on the basis of the European Randomized Study of Screening for Prostate Cancer (ERSPC) (Current Controlled Trials number, ISRCTN49127736 [controlled-trials.com] ), that screening with prostate-specific antigen (PSA) saves lives (March 26 issue). The PLCO trial is being portrayed as the underpinning for proposed changes in the mind-set of physicians and patients that prostate-cancer screening and treatment do more harm than good. However, the PLCO . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.